Venous thromboembolism (VTE) is the third most common cause of death worldwide. The
incidence of VTE varies according to different countries, ranging from 1–2 per 1000 person …

Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

This guidance focuses on methodological aspects of lupus anticoagulant (LA) testing, as
well as interpretation of results for clinicians. The main changes in how to test for LA …

Our objective was to update the EULAR recommendations for the management of systemic
lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic …

Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …

Antiphospholipid Syndrome Antiphospholipid antibodies can induce endothelial-cell,
complement, platelet, neutrophil, and monocyte activation, leading to thrombosis, renal …

Immune-related manifestations are increasingly recognized conditions in patients with
COVID-19, with around 3,000 cases reported worldwide comprising more than 70 different …

Background: The potential role of new oral anticoagulants in antiphospholipid antibody
syndrome (APS) remains uncertain. Objective: To determine whether rivaroxaban is …

Background High incidence of thrombosis in COVID‐19 patients indicates a
hypercoagulable state. Hence, exploring the involvement of antiphospholipid antibodies …